Drug Database
Back to search

Switzerland· 69063003

Sogroya 15 mg/ 1.5 ml, Injektionslösung im Fertigpen

A somapacitan product containing somapacitanum, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC H01AC07

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedSogroya 15 mg/ 1.5 ml, Injektionslösu…ATCH01AC07REGISTER NO.69063003PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about somapacitanumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Somapacitan is registered in 13 of 19 countries.

Countries holding a registration under ATC H01AC07 (somapacitan), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose
Search somapacitan products by name

Somapacitan · ATC H01AC07

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
somapacitanum
Manufacturer
Novo Nordisk Pharma AG
Country
Switzerland (CH)
ATC code
H01AC07
ATC class
Somapacitan
Defined daily dose
0.6 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680690630034
    Fertpen 1.5 ml
    CHF 799.1

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

303 interactions on record for somapacitan.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check somapacitan against other medicinesHow interaction checks work

Somapacitan · interactions on record

303 records

  • 2 severe
  • 296 moderate
  • 5 minor

Most severe, free to view

  • OmeprazoleA02BC01moderate
  • PantoprazoleA02BC02moderate
  • LansoprazoleA02BC03moderate
  • RabeprazoleA02BC04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Somapacitan in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All somapacitan products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Sogroya
  • Norway · Sogroya

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/69070a44-ecc6-469d-825e-5b5ba6781e04
GET /v1/drugs/69070a44-ecc6-469d-825e-5b5ba6781e04?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "somapacitanum 15 mg",
  "valid_from": "2024-10-01",
  "limitations": "[{\"description\":\"SOGROYA wird vergütet für die Substitution des endogenen Wachstumshormons (Growth Hormone, GH) bei pädiatrischen Patienten ab dem Alter von 3 Jahren mit Wachstumsstörungen aufgrund eines nachgewiesenen Wachstumshormonmangels (Growth Hormone Deficiency, GHD). Andere Ursachen der Wachstumsstörung müssen ausgeschlossen sein.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-10-01\"}]",
  "galenic_form": "Inj Lös 15 mg/1.5ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-10-01",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about somapacitan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console